Now showing items 1-10 of 27
Effectiveness of hyperbaric oxygen for experimental treatment of schistosomiasis mansoni using praziquantel-free and encapsulated into liposomes: Assay in adult worms and oviposition
(Elsevier B. V., 2015)
The treatment of schistosomiasis depends on a single drug: praziquantel (PZQ). However, this treatment presents limitations such as low and/or erratic bioavailability that can contribute to cases of tolerance. Improvements ...
Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes
(Elsevier B.V., 2005-05-13)
Praziquantel (PZQ) is effective against all known species of Schistosomes that infect humans. The failure of mass treatment of schistosomiasis has been attributed to the fact that therapy is not sufficiently long-lasting. ...
Liposomal-praziquantel: Efficacy against Schistosoma mansoni in a preclinical assay
Currently, schistosomiasis mansoni is treated clinically with praziquantel (PZQ). Nevertheless, cases of tolerance and resistance to this drug have been reported, creating the need to develop new drugs or to improve existing ...
Efeito do praziquantel incorporado a lipossomas nos diferentes estágios de desenvolvimento dos ovos de Schistosoma mansoni
Mansonian schistosomiasis is caused by an intravascular digenetic trematode Schistosoma mansoni. Praziquantel (PZQ) and oxamniquine (OXA) are the drugs of choice for the treatment of this disease. However, both drugs are ...